Efficacy for PTCL according to cohort
| Cohorts . | Total treated . | Total evaluable for response . | ORR . | CBR . | CR . | PR . | SD >6 mo . |
|---|---|---|---|---|---|---|---|
| Cohort 1 | 19 | 19 | 7 (37%) | 10 (53%) | 1 (5%) | 6 (32%) | 3 (16%) |
| Cohort 2 | 12 | 11 | 4 (36%) | 5 (45%) | 2 (18%) | 2 (18%) | 1 (9%) |
| Cohort 3 | 15 | 15 | 1 (7%) | 2 (13%) | 0 (0%) | 1 (7%) | 1 (7%) |
| Total | 46 | 45 | 12 (27%) | 17 (38%) | 3 (7%) | 9 (20%) | 5 (11%) |
| P (cohorts 1 & 2 vs 3) | ORR, P = .04 | CBR, P = .02 | |||||
| Cohorts . | Total treated . | Total evaluable for response . | ORR . | CBR . | CR . | PR . | SD >6 mo . |
|---|---|---|---|---|---|---|---|
| Cohort 1 | 19 | 19 | 7 (37%) | 10 (53%) | 1 (5%) | 6 (32%) | 3 (16%) |
| Cohort 2 | 12 | 11 | 4 (36%) | 5 (45%) | 2 (18%) | 2 (18%) | 1 (9%) |
| Cohort 3 | 15 | 15 | 1 (7%) | 2 (13%) | 0 (0%) | 1 (7%) | 1 (7%) |
| Total | 46 | 45 | 12 (27%) | 17 (38%) | 3 (7%) | 9 (20%) | 5 (11%) |
| P (cohorts 1 & 2 vs 3) | ORR, P = .04 | CBR, P = .02 | |||||